The China Pharmaceutical Distributors Alliance Conference, organized by West Summit (Xiding) and held on March 28, 2026, at Ruifeng Hotel, convened industry leaders from pharmaceutical manufacturing, distribution, and retail pharmacy sectors under the theme “Uniting Forces to Break Through: Category Innovation as a New Growth Engine for OTC and Third-Tier Healthcare Channels.” The event centered on actionable strategies to revitalize distributor and pharmacy performance amid evolving market dynamics.
Li Shengta, General Manager of Guangdong Jundao Fanglüe Brand Operations Co., Ltd. and a recognized authority in pharmacy strategic growth and non-pharmaceutical (non-drug) category marketing, delivered a keynote address titled “From Dispensing Medications to Managing Health: How Non-Drug Categories Are Reshaping Pharmacy Growth Logic.” His presentation—grounded in field-tested frameworks rather than theoretical concepts—offered a comprehensive roadmap for integrating health-focused non-drug offerings into core pharmacy operations. In recognition of his expertise, Li was formally appointed Dean of the newly established China Pharmaceutical Distributors Self-Governance Alliance Development Research Institute.
The conference prioritized three interlocking imperatives: category innovation, non-drug diversification, and digital transformation. Li’s analysis underscored a pivotal shift underway across China’s pharmacy landscape—driven by national policy directives encouraging community pharmacies to evolve into “health service hubs.” Supporting this transition, data from China’s leading healthcare intelligence firm Kangchuang reveals that pharmacies generating more than 30% of revenue from non-drug categories consistently outperform industry benchmarks in both average store sales and gross margin—confirming non-drug expansion as a structural driver of sustainable profitability.
Yet Li cautioned that many pharmacies struggle with fragmented category planning and insufficient clinical or lifestyle-health competency among frontline staff. To overcome these barriers, he advocated a tripartite foundation: professional credibility (anchored in evidence-based pharmaceutical services), contextual relevance (tailoring offerings to real-world health needs), and experiential engagement (designing touchpoints that foster trust and behavior change). Critically, he emphasized that non-drug success does not diminish the centrality of medicines—it amplifies their value through integrated, patient-centered care models.
For practical implementation, Li introduced several proprietary, scalable frameworks. His “Four-Dimensional Product Selection Radar” guides assortment strategy across four functional roles: high-frequency traffic drivers, high-margin staples, experience-enhancing items (e.g., wearable wellness tech or personalized skincare diagnostics), and bundled health solutions (e.g., menopause support kits or post-surgical scar management systems). He identified eight high-potential health economy segments—including women’s health, healthy aging, and chronic disease self-management—as priority growth corridors, urging distributors and retailers to align product curation with demographic and behavioral insights (e.g., targeting “she-economy” consumers or hypertension patients).
Operationally, Li proposed a “Community × Live Streaming × Private Domain” marketing architecture—leveraging segmented WeChat communities, live-video consultations with pharmacists or nutritionists, and CRM-integrated follow-up—to shift from transactional selling to longitudinal health relationship management. On the physical environment front, he detailed five signature micro-scenarios: home medicine cabinet optimization zones, holistic beauty-and-wellness stations, wound-and-acne counseling centers, senior-friendly pharmacy layouts, and pediatric health navigation corners. Each is designed to convert passive browsing into active health decision-making through immersive, low-friction experiences.
Throughout his presentation, Li wove in two proprietary profitability models—the “Non-Drug Golden Triangle” (balancing clinical alignment, consumer desirability, and operational scalability) and the “1+N Omni-Channel Profit Model” (where one anchor health service catalyzes multiple complementary revenue streams)—illustrating each with real-world case studies from tier-two and tier-three markets. Attendees responded with sustained applause and rapid note-taking, describing the content as “immediately applicable” and “rigorously practical.”
The appointment of Li Shengta as Dean of the Alliance Development Research Institute marks a strategic commitment to evidence-informed advancement within the pharmaceutical distribution ecosystem. Endorsed by Cheng Jizhong, Strategic Advisor to Harbin Pharmaceutical Group, the role formalizes Li’s mandate to translate frontline operational insights into scalable research, policy recommendations, and capacity-building programs for distributors nationwide.
This leadership appointment reflects broad consensus that non-drug category excellence is no longer peripheral—it is foundational to pharmacy resilience, differentiation, and long-term viability. As Li assumes his new responsibilities, his mission remains clear: to equip distributors and retailers with clinically grounded, commercially viable tools that accelerate the sector-wide evolution from medication dispensing to holistic health stewardship—advancing quality, accessibility, and sustainability across China’s healthcare delivery system.